These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 38223415)

  • 1. From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: Controversy and consensus.
    Chen L
    World J Hepatol; 2023 Dec; 15(12):1253-1257. PubMed ID: 38223415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD.
    Abdelhameed F; Kite C; Lagojda L; Dallaway A; Chatha KK; Chaggar SS; Dalamaga M; Kassi E; Kyrou I; Randeva HS
    Curr Obes Rep; 2024 May; ():. PubMed ID: 38809396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of nomenclature as metabolic associated steatotic liver disease on steatotic liver disease prevalence and screening: a prospective population survey in Asians.
    Wu T; Ye J; Mo S; Ye M; Li X; Li Q; Wang W; Zheng Q; Luo K; Zhang Y; Tu S; Che D; Gong R; Chen X; Miu R; Shao C; Sun Y; Zhong B
    J Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38695344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence.
    Gao J; Li Y; Zhang Y; Zhan X; Tian X; Li J; Wang R; He Y; Wang A; Wu S
    J Am Heart Assoc; 2024 Mar; 13(5):e032604. PubMed ID: 38390843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity.
    Kim GA; Moon JH; Kim W
    Clin Mol Hepatol; 2023 Oct; 29(4):831-843. PubMed ID: 37634892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steatotic liver disease, MASLD and risk of chronic kidney disease.
    Bilson J; Mantovani A; Byrne CD; Targher G
    Diabetes Metab; 2024 Jan; 50(1):101506. PubMed ID: 38141808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update in lean metabolic dysfunction-associated steatotic liver disease.
    Sato-Espinoza K; Chotiprasidhi P; Huaman MR; Díaz-Ferrer J
    World J Hepatol; 2024 Mar; 16(3):452-464. PubMed ID: 38577539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breaking new ground: MASLD vs. MAFLD-which holds the key for risk stratification?
    Ramírez-Mejía MM; Jiménez-Gutiérrez C; Eslam M; George J; Méndez-Sánchez N
    Hepatol Int; 2024 Feb; 18(1):168-178. PubMed ID: 38127259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From Liver to Brain: How MAFLD/MASLD Impacts Cognitive Function.
    Medina-Julio D; Ramírez-Mejía MM; Cordova-Gallardo J; Peniche-Luna E; Cantú-Brito C; Mendez-Sanchez N
    Med Sci Monit; 2024 Jan; 30():e943417. PubMed ID: 38282346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the landscape of steatotic liver disease in the general US population.
    Ciardullo S; Carbone M; Invernizzi P; Perseghin G
    Liver Int; 2023 Nov; 43(11):2425-2433. PubMed ID: 37592856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in the prevalence of NAFLD, MAFLD, and MASLD according to changes in the nomenclature in a health check-up using MRI-derived proton density fat fraction.
    Park HJ; Lee S; Lee JS
    Abdom Radiol (NY); 2024 Apr; ():. PubMed ID: 38587630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing similarities and differences between NAFLD, MAFLD, and MASLD in the general U.S. population.
    Zou H; Ma X; Pan W; Xie Y
    Front Nutr; 2024; 11():1411802. PubMed ID: 39040926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative associations of MASLD and MAFLD with the presence and severity of coronary artery calcification.
    Kang MK; Song J; Loomba R; Park S; Tak W; Kweon Y; Lee Y; Park JG
    Res Sq; 2024 Mar; ():. PubMed ID: 38496485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deciphering metabolic dysfunction-associated steatotic liver disease: insights from predictive modeling and clustering analysis.
    Mori K; Akiyama Y; Tanaka M; Sato T; Endo K; Hosaka I; Hanawa N; Sakamoto N; Furuhashi M
    J Gastroenterol Hepatol; 2024 Jul; 39(7):1382-1393. PubMed ID: 38629681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Independent and joint association of physical activity and adequate weekday sleep duration with metabolic dysfunction-associated steatotic liver disease.
    Li Y; Guo Y; Tan S
    Clin Res Hepatol Gastroenterol; 2024 Apr; 48(4):102320. PubMed ID: 38484840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis of non-alcoholic fatty liver disease differences from metabolic dysfunction-associated fatty liver disease based on clinical features].
    Liu YX; Guo F; Niu LN; Zhang B; Dou J; Xu Q; Ning ZH; Wang XZ
    Zhonghua Gan Zang Bing Za Zhi; 2024 Apr; 32(4):346-353. PubMed ID: 38733190
    [No Abstract]   [Full Text] [Related]  

  • 17. [Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases].
    Chen L; Jiang LN; Zhao JM
    Zhonghua Gan Zang Bing Za Zhi; 2023 Aug; 31(8):805-809. PubMed ID: 37723061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma.
    Wang Y; Fleishman JS; Li T; Li Y; Ren Z; Chen J; Ding M
    Front Pharmacol; 2023; 14():1336216. PubMed ID: 38313077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
    Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
    Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults.
    Song R; Li Z; Zhang Y; Tan J; Chen Z
    Liver Int; 2024 Apr; 44(4):1051-1060. PubMed ID: 38293788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.